Selective serotonin re-uptake inhibitors for premature ejaculation in adult men

Sathianathen, Niranjan; Hwang, Eu Chang; Mian, Ruma; Bodie, Joshua; Soubra, Ayman; Lyon, Jennifer; Sultan, Shahnaz; Dahm, Philipp

doi:10.1002/14651858.cd012799.pub2

Cited by 9 publications

(7 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GRADE summary of findings is outlined in Table 1 . A detailed description of the results of this review including the subgroup analyses is available in the original review [ 49 ].…”

Section: Resultsmentioning

confidence: 99%

Selective Serotonin Re-Uptake Inhibitors for Premature Ejaculation in Adult Men: A Cochrane Systematic Review

Sathianathen

Hwang

Mian

et al. 2022

World J Mens Health

Self Cite

View full text Add to dashboard Cite

Purpose Selective serotonin re-uptake inhibitors (SSRIs) are frequently used to treat premature ejaculation (PE) in men. We performed a Cochrane review to assess the efficacy of SSRI treatment for PE. Materials and Methods We extensively searched a range of databases up to May 2020 and only included randomized controlled trials. Results A total of 31 studies with 8,254 men were included in this analysis. We found that SSRI treatment probably improves self-perceived PE symptoms (defined as a rating of ‘better’ or ‘much better’; risk ratio [RR], 1.92; 95% confidence interval [CI], 1.66–2.23; moderate-certainty evidence) and satisfaction with intercourse (defined as a rating of ‘good’ or ‘very good’; RR, 1.63; 95% CI, 1.42–1.87; moderate-certainty evidence) compared to placebo. Furthermore, SSRI treatment likely improve participants’ self-perceived control over ejaculation (defined as rating of ‘good’ or ‘very good’; RR, 2.29; 95% CI, 1.72–3.05; moderate-certainty evidence) and probably lessens distress (defined as rating of ‘a little bit’ or ‘not at all’) about PE (RR, 1.54; 95% CI, 1.26–1.88; moderate-certainty evidence). SSRI treatment may increase IELT compared to placebo (mean difference, 3.09 minutes higher; 95% CI, 1.94 higher to 4.25 higher; low-certainty evidence). However, SSRIs may increase treatment cessations due to adverse events compared to placebo (RR, 3.80; 95% CI, 2.61–5.51; low-certainty evidence). Conclusions SSRI treatment for PE appears to substantially improve a number of outcomes of direct patient importance such as symptom improvement, satisfaction with intercourse and perceived control over ejaculation when compared to placebo.

show abstract

“…The GRADE summary of findings is outlined in Table 1 . A detailed description of the results of this review including the subgroup analyses is available in the original review [ 49 ].…”

Section: Resultsmentioning

confidence: 99%

Selective Serotonin Re-Uptake Inhibitors for Premature Ejaculation in Adult Men: A Cochrane Systematic Review

Sathianathen

Hwang

Mian

et al. 2022

World J Mens Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although SSRI/SNRI drugs were first introduced as mood stabilizers, their indication now has been extended to the treatment of other disorders 51–54 . Considering the proposed mechanisms, it is somehow logical to consider these medications as an adjunct in the treatment of infectious diseases such as COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID‐19 patients: A systematic review and meta‐analysis

Firouzabadi

Kheshti

Abdollahifard

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aim Due to the high social and economic burden and also mortality and morbidity caused by coronavirus disease 2019 (COVID‐19) in the past few years, researchers have aimed at finding solutions to suppressing the severity of infection. Recently, selective serotonin and serotonin‐norepinephrine reuptake inhibitors (SSRI/SNRI) have been investigated as an adjuvant treatment for COVID‐19. The aim of the current study was to investigate the impact of SSRI/SNRIs on outcomes of COVID‐19 patients. Methods In this systematic review and meta‐analysis, a comprehensive search strategy consisting of relevant words was performed by two researchers in PubMed, Scopus and EMBASE libraries. Studies reporting the effect of SSRI and/or SNRI use in COVID‐19 patients' outcome were included. Hospitalization, mortality, hospitalization event, and length of hospital stay were considered as main outcomes of this study. Analysis was carried out using Comprehensive Meta‐Analysis (CMA‐version 2) and final data were reported as odds ratio (OR) and 95% confidence interval (CI). Results Our search led to the final selection of 9 articles including 15,287 patients. The effect of fluvoxamine, fluoxetine, and the overall effect of SSRI/SNRI use on mortality of COVID‐19 patients were investigated in 3, 2, and 7 articles, respectively. The results of our analyses showed that these medications could significantly decrease mortality of COVID‐19 patients (OR and 95% [CI]: 0.595 [0.467–0.758], 0.620 [0.469–0.821], and 0.596 [0.437–0.813]). The effect of SSRI/SNRIs on hospitalization events of COVID‐19 patients was not significant (OR: 0.240% and 95% CI: 0.041–1.4). Also, length of hospital stay was longer in patients who administrated SSRIs. Conclusion According to this study's results, SSRI/SNRIs may be effective in reducing mortality of COVID‐19 patients, suggesting the superiority of fluvoxamine to fluoxetine. The safety profile and affordable cost of SSRI/SNRIs for a short‐term use may be other reasons to propose them as beneficial medications in preventing mortality in COVID‐19.

show abstract

“…In this contest, it is also interesting to note that a frequent off-label prescription for some SSRIs, including paroxetine, fluoxetine, sertraline and escitalopram, is premature ejaculation (Arafa & Shamloul 2007, Balon 1996. A recent Cochrane review supports their use to treat this condition (Sathianathen et al 2021). In addition to the sexual problems observed during treatment, recently, the persistence of sexual dysfunction after stopping SSRI drugs has been increasingly reported (Bala et al 2018, Patacchini & Cosci 2021, Patacchini & Cosci 2020, Rothmore 2020, Reisman 2017, Reisman 2020, Healy 2019, Healy 2020, Healy et al 2018, Hogan et al 2014.…”

Section: Introductionmentioning

confidence: 99%